Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Pla...
February 14 2017 - 4:30PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announces the appointment of Christel Iffland, Ph.D. as a Vice
President of Antibody Technologies.
Dr. Iffland joins Ligand from Merck KGaA/EMD Serono where she
served as Group Leader of Antibody Display Technologies, a Senior
Scientist of Phage Technologies and Structural Biology and
Associate Director of Antibody Technologies. At Ligand, Dr. Iffland
will support current and new partnerships and collaborations for
the OmniAb franchise, providing scientific guidance and input.
Additionally, she will contribute to the continued growth and
next-generation innovation of OmniAb and to the technical
assessment of new opportunities.
“Christel has been a longtime user of the OmniAb technology and
we are delighted to welcome her to Ligand as we further expand our
scientific team focused on antibodies and antibody technologies,”
said John Higgins, Ligand’s Chief Executive Officer. “Our
acquisition of the OmniAb technology last year transformed and
expanded Ligand’s business model. Antibody treatments are the
fastest-growing segment of the pharmaceutical industry and will
continue to be an important area of focus for Ligand as we expand
our portfolio of more than 150 fully-funded shots-on-goal.”
Dr. Iffland received her Ph.D. in Molecular and Cell Biology
from the Université de Nice Sophia-Antipolis in Nice, France and
completed post-doctoral research training at both the Dana-Farber
Cancer Institute at Harvard Medical School and the Albert Einstein
College of Medicine. Dr. Iffland is an author of numerous
scientific publications and patents and is a prior recipient of the
Merck Award for Patent and Inventorship.
About OmniAb®
OmniAb includes three transgenic animal platforms for producing
mono- and bispecific human therapeutic antibodies. OmniRat® is the
industry’s first human monoclonal antibody technology based on
rats. It has a complete immune system with a diverse antibody
repertoire and generates antibodies with human idiotypes as
effectively as wild-type animals make rat antibodies. OmniMouse® is
a transgenic mouse that complements OmniRat and expands epitope
coverage. OmniFlic® is an engineered rat with a fixed light chain
for development of bispecific, fully human antibodies. The three
platforms use patented technology, have broad freedom to operate
and deliver fully human antibodies with high affinity, specificity,
expression, solubility and stability.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
Forward-Looking Statements
This news release contains forward-looking statements by Ligand
that involve risks and uncertainties and reflect Ligand's judgment
as of the date of this release. Actual events or results may differ
from our expectations. For example, there can be no assurances that
Ligand will be able to develop a next-generation OmniAb technology
or that the antibody treatments will continue to be the
fastest-growing segment of the pharmaceutical industry. The failure
to meet expectations with respect to any of the foregoing matters
may reduce Ligand's stock price. Additional information concerning
these and other important risk factors affecting Ligand can be
found in Ligand's prior press releases available at www.ligand.com
as well as in Ligand's public periodic filings with the Securities
and Exchange Commission, available at www.sec.gov. Ligand disclaims
any intent or obligation to update these forward-looking statements
beyond the date of this press release, except as required by law.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170214006358/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill, (858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss, (310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024